SOAT1 and pachyonychia congenita: Pharmacological inhibitors such as niclosamide, fludarabine and ruxolitinib that block JAK-STAT signaling have the ability to resensitize Enz-resistant cells, indicating that JAK-STAT signaling may generally contribute to drug therapy resistance in PC The JAK/STAT pathway in therapy resistance is illustrated below in Figure 2.